Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis (CP3)

Change in LDL cholesterol

Percent newly using lipid lowering, hypertension (HTN), or diabetes (DM) medications

Change in predicted 10-year risk of atherosclerotic cardiovascular disease (ASCVD) among patients with baseline 10-year risk greater than or equal to 5% measured by the American College of Cardiology ASCVD risk estimator tool for predicting percent risk for atherosclerotic cardiovascular disease.

Percent with 7.5% to 20% risk who achieve a 30% or greater reduction in LDL on follow up testing

Percent with greater than or equal to 20% risk who achieve LDL reduction of greater than or equal to 50%

Percent who achieve LDL less than 100 mg/dL or non-HDL less than 130 mg/dL

Change in systolic blood pressure (mm Hg)

Change in total cholesterol (mg/dL)

Change in HDL cholesterol (mg/dL)

Change in non-HDL cholesterol (mg/dL)

Change in hemoglobin A1c level measured in percent.

Change in weight calculated by BMI (kg/m2)

Percent of patients who quit smoking measured by self-reported response to survey question.

Percent undergoing additional cardiovascular (CV) risk testing such as stress test, coronary calcium score or related imaging.

Change in percent of body surface area affected by psoriasis will be assessed.

Change in PGA score measured from 0-5 with 5 being the most severe psoriasis and 0 being the least severe.

Patient reported quality of life outcomes will be assessed using DLQI. The DLQI is calculated by summing the score of 10 questions regarding impact of skin condition on daily life resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale ranging from 1 (no health state problem) to 3 (extreme health state problems). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale ranging from 0, worst health state, to 100, best health state. A scoring function is used to assign a value (i.e., EQ-5D™ index score) to self-reported health states from a set of population-based preference weights. For the U.S. general population, the possible EQ-5D index scores range from -0.11 to 1.0 where 0.0 = death and 1.0 = perfect health.

Proportion of patients who have reported any change in medications taken for psoriatic disease measured through a patient reported survey.

Change in patient reported physcial activity level through the Physical Activity Questionnaire measuring the number of days active for at least 30 minutes over the past month

Change in patient reported physcial activity level through the Physical Activity Questionnaire measuring the patient reported level of physical activity on a likert scale from seldom active to vigorously active.

Patient experience with the care coordinator will be measured through the Patient Experience Survey with a likert scale from strongly agree to strongly disagree.